ABSTRACT
This brief review will highlight recent advances in understanding the molecular and genetic basis of obesity made by using animal models or human studies. Some of the most promising research directions and their implications for therapeutic drug development will be discussed.
SINGLE GENE DEFECTS

IN OBESITY
Table 1 isa summary of the singlegene defectsin rodent models of obesity and our understanding of their molecular basis. The first geneticdefectto be described and the first to be cloned was the one that produces the yellow obese mouse. Overexpression of the agouti signaling protein, a 133 amino acid protein, is responsible for the hyperphagia, obesity, and yellow coat color of these mice. The peptide appears to interact with the melanocyte-stimulating hormone receptor, which can explain the defects this animal displays.
The two most widely studied-the obese mouse and diabetes mouse-were found to have a defect in the production of a circulating factor called leptin (ob/ob) (2) and in the leptin receptor (db/db) (3-5), as had been suggested by Coleman (6) in his prescient parabiosis studies. Cloning of the defective gene in the ob/ob mouse was accomplished by Zhang et al. (2) in 1994. This genetic defect resulted from a single base substitution, which produced a stop codon at amino acid 105 in a peptide that is normally 167 amino acids in length.This pepude has been named leptin from "leptos," the Greek word for thin. Leptin is produced exclusively in adipose tissue, and when injected into the ob/ob mouse, which isdeficientin thispeptide, itwillreduce food intake, reduce body weight, increase energy expenditure, and repair reproductive function (7-9). In the db/db mouse, which has a defect in the leptin receptor, there islittle or no weight lossor decrease in food intake after leptin injection (7, 9, 10 reproduction. The hyperphagia observed in leptindeficientob/ob mice may in part reflecttheireffort to increase fat stores to "turn on" their reproductive system. Ifsuch an interpretationis correct, then one potentialconsequence of excess amounts of leptinin the very obese woman might be disruption of the reproductive system, a well-known phenomenon in many obese people.
The fattyrat isthe only geneticallyobese rat,and ithas a defect in the leptinreceptor on chromosome 5 that issimilarto that in the db/db mouse. Unlike the db/db mouse, however, the fatty rat is not hyperglycemic and diabetic, The final pair of defects are in the fat and tub mouse. The fatmouse isa recessively inherited defect with mild obesityand high levelsof circulatingpromsulin.This finding led to testingthe hypothesis that this defect might be due to a processing defect in peptide cleavage enzymes. Carboxypeptidase E was found to be deficient and to account for the syndrome.
The defect in the tub mouse is also recessive, but only time will tell whether the phosphatase defect originally suggested is correct. The discovery of leptin has generated great excitement. It has served as a major piece of evidence that obesity is a serious disease and can be produced by genetic and molecular abnormalities. It should be kept in mind, however, that the effectsof leptindeficiency are critically dependent on adrenal glucocorticoids(13).Adrenalectomy in the ob/ob mouse, the db/db mouse, and all the other animals listed in Table  1 any of the markers and obesity in these families. However, before definitively excluding these chromosomal regions as potential carriers of loci predisposing to obesity in clinically normal subjects, other studies with more genetic markers will have to be performed. Table 3 lists several transgenic and knockout mice that have been shown to modify body fat (24-31). Each of these transgenic animals provides some insight into important systems that are perceived to be physiologically involved in the regulation of food intake, fat stores, and energy expenditure.
TRANSGENIC MODELS
OF OBESITY
As noted above, glucocorticoids significantly block the effectof leptin deficiency as well as the defect in the leptin receptor. The finding that an anti-sense gene for the glucocorticoid receptor in the brain would lead to slowly developing obesity was of interest because this anti-sense transgene to the glucocorticoid receptor should partly knock out the receptor (28) and lead to overexpression of CRH and adreno- elevated glucocorticoid secretion or is related in part to the enhanced processing of POMC to produce
ACTH, along with a-MSH, is unclear (30).
The knockout of the uncoupling protein in brown adipose tissueisa second model of particularinterest (27).This knockout transgene increasesfood intake and decreases thermic response to diet, particularly in males. This suggests that the ability to enhance heat production by food may play a role in the chronic setting of food intake and energy storage levels. This finding may be part of a reciprocal response of food intake and the sympathetic nervous system that has been shown in a variety of experimental settings (32).
In addition to the transgenes that produce obesity or increase body fat,other transgenes will reduce body fat. Just as overexpression of the glut-4 gene will increase body fat, so will knocking out thisgene decrease body fat. Overexpression of lipoprotein lipase in muscle isassociatedwith a small decrease in body fat.Similarly,overexpression of two genes that can increase heat dissipationwill reduce body fat.The insights each of these transgenes provides can be translatedinto new ideas about the development of drugs to treat obesity effectively. In both of these studies,there was no evidence of linkage when sibswere discordant for obesityor when the BMI was less than 35 (39) or 40 (38). Finally, on the basis of data from the San Antonio Family Diabetes Study, a significantlinkage was reported between D7S514 and the sum of five limb skinfolds (40).Weaker evidence for linkage was also observed for BMI and fatmass with a locus about 15 cM telmeric to OB.
LINKAGE RESULTS IN HUMANS
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RESEARCH DIRECTIONS
As argued before, the bulk of the ongoing research in this field focuses on the molecular mechanisms of appetite and satietyregulation, energy metabolism, nutrient partitioning, and adipose celldifferentiation and enlargement. This islikelyto provide geneticists with a whole new generation of candidate genes to explore for DNA sequence variation and relationships with body fat content and proneness to become obese with age. Among the molecules of greatest interest at this time, one can identify the following: the single mouse model of obesity gene products (leptin, leptin receptors, agouti signaling protein, carboxypeptidase E, etc.; see Only one family study has so far reported results of a genome-wide search to uncover markers linked with body fat, and it was conducted on the Pima Indians (41).There are, however, other genome-wide search initiatives currently in progress, and we should benefit from these studies as soon as they become available. This raisesthe issue of cooperative research efforts. Indeed, it would be of great advantage if data from the ongoing family studies of obesity could be pooled or merged for selected analysis so that the ability to identify the contribution of specific genes could be enhanced.
Another strategy would be to ensure that the results from one family study are replicated in another or several such studies. Without combining data sets or systematically replicating the data of one another, the ongoing family studies are likely to generate several false positive or false negative results.
CLINICAL APPLICATIONS
The rapid development in understanding the physiology regulating energy or nutrient intake and energy expenditure along with the insights provided from the study of genetic factorsin the pathogenesis of obesityoffersnew avenues for clinical applications of drug development teams. A listof some potential avenues for the development of drugs to treatobesity ispresented in Table  4 . Blockade of the neuronal reuptake of serotonin (fenfluramine, dexfenfluramine, fluoxetine,and sertraline) or of both serotonin and norepinephrine (NE) (sibutramine and venlafaxine) represents one such avenue. Dexfenfluramine has also been shown 
151
